Enrique María
Ocio San Miguel
Publicaciones en las que colabora con Enrique María Ocio San Miguel (17)
2022
-
Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma
Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 21, pp. 4771-4781
2019
-
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Leukemia, Vol. 33, Núm. 5, pp. 1256-1267
2016
-
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
Blood, Vol. 127, Núm. 25, pp. 3165-3174
-
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: A new model to understand chemoresistance
Blood, Vol. 127, Núm. 15, pp. 1896-1906
2015
-
Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential
Leukemia, Vol. 29, Núm. 5, pp. 1186-1194
-
The cellular origin and malignant transformation of Waldenström macroglobulinemia
Blood, Vol. 125, Núm. 15, pp. 2370-2380
2014
2013
-
A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control
Leukemia, Vol. 27, Núm. 10, pp. 2056-2061
-
Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry
Haematologica, Vol. 98, Núm. 1, pp. 79-86
-
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile
Blood, Vol. 122, Núm. 22, pp. 3591-3598
-
Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control (Leukemia (2013) 27 (2112))
Leukemia
2012
-
CD20 positive cells are undetectable in the majority of multiple myeloma cell lines and are not associated with a cancer stem cell phenotype
Haematologica, Vol. 97, Núm. 7, pp. 1110-1114
2011
-
Post-treatment bone marrow residual disease > 5% by flow cytometry is highly predictive of short progression-free and overall survival in patients with Waldenström's macroglobulinemia.
Clinical lymphoma, myeloma & leukemia, Vol. 11, Núm. 1, pp. 168-171
2005
-
Cell cycle analysis of Waldenström's macroglobulinemia
Clinical Lymphoma, Vol. 5, Núm. 4, pp. 250-252
-
Immunophenotypic and cytogenetic comparison of Waldenström's macroglobulinemia with splenic marginal zone lymphoma
Clinical Lymphoma, Vol. 5, Núm. 4, pp. 241-245
2003
-
Immunophenotypic analysis of Waldenstrom's macroglobulinemia
Seminars in Oncology, Vol. 30, Núm. 2, pp. 187-195
2002
-
Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival
British Journal of Haematology, Vol. 118, Núm. 4, pp. 1034-1040